Viewing Study NCT00625313


Ignite Creation Date: 2025-12-18 @ 9:44 AM
Ignite Modification Date: 2025-12-23 @ 9:59 PM
Study NCT ID: NCT00625313
Status: None
Last Update Posted: 2015-08-19 00:00:00
First Post: 2008-02-19 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Clinical Study of a UV-Absorbing Acrylic Posterior Chamber Intraocular Lens
Sponsor: None
Organization:

Study Overview

Official Title: A Prospective, Multi-center, Single-phase, Non-randomized, Open-label Study to Assess the Safety and Efficacy of the HMY Model YA-60BB Intraocular Lens (IOL) for the Correction of Aphakia Following Phacoemulsification Cataract Extraction
Status: None
Status Verified Date: 2015-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HMY
Brief Summary: A prospective, single-phase, non-randomized, open-label study to include patients with operable cataract of the human crystalline lens who have a potential post-operative best corrected visual acuity of 20/40 or better and no pre-existing progressive sight-threatening ocular disorders. Patients who are eligible per inclusion / exclusion criteria will undergo phacoemulsification cataract extraction and then implantation of the Hoya HMY Model YA-60BB posterior chamber intraocular lens. Each patient will be followed-up at specific time intervals to assess safety and effectiveness, for up to 36 months.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: